Physician profile
Athanasios G Papastamelos
NPI 1821051277
$7,617.68
in general payments reported to CMS, 2019-2025
36 companies · $1,846 in 2025
The $1,846 reported for 2025 was more than what 85% of Infectious Disease providers received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,067 · 2020: $269 · 2021: $429 · 2022: $865 · 2023: $1,681 · 2024: $1,462 · 2025: $1,846.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,925 · Education: $63.15.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,925.01 |
| Education | $63.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,121.63 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $910.72 | 2019-2025 | Pifeltro, Dificid, Delstrigo |
| Viiv Healthcare Company | $882.59 | 2019-2025 | Rukobia, Dovato, Cabenuva |
| Insmed, INC. | $843.17 | 2019-2025 | Arikayce, Brinsupri |
| Gilead Sciences, INC. | $482.74 | 2019-2025 | Epclusa, Biktarvy |
| Teva Pharmaceuticals USA, INC. | $427.21 | 2022-2025 | Austedo Xr, Austedo, Austedo Xr |
| Allergan, INC. | $298.15 | 2019-2020 | |
| Sk Life Science, INC. | $265.81 | 2022-2024 | Xcopri |
| Amgen INC. | $262.47 | 2021-2025 | Evenity |
| Astrazeneca Pharmaceuticals Lp | $258.47 | 2021-2025 | Breztri |
| Acadia Pharmaceuticals INC | $253.17 | 2023 | Nuplazid |
| Janssen Pharmaceuticals, INC | $157.24 | 2024 | Xarelto |
| Ucb, INC. | $124.85 | 2024 | Nayzilam |
| Ani Pharmaceuticals, INC. | $123.99 | 2023 | Purified Cortrophin Gel |
| Sumitomo Pharma America, INC. | $123.61 | 2023 | Gemtesa |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $122.53 | 2023 | Mounjaro |
| Celgene Corporation | $122.40 | 2021 | |
| Idorsia Pharmaceuticals US INC | $120.29 | 2023 | Quviviq |
| Smith+Nephew, INC. | $112.40 | 2019-2025 | Collagenase Santyl |
| Paratek Pharmaceuticals, INC. | $112.08 | 2019-2025 | Nuzyra |
| Shionogi INC | $101.46 | 2024-2025 | Fetroja |
| Takeda Pharmaceuticals U.S.A., INC. | $71.13 | 2024-2025 | Hyqvia |
| Melinta Therapeutics, LLC | $54.45 | 2019 | |
| Janssen Biotech, INC. | $51.01 | 2019-2022 | |
| Napo Pharmaceuticals INC | $31.37 | 2024-2025 | Mytesi |
| Glaxosmithkline, LLC. | $28.22 | 2019 | |
| Urgo Medical North America, LLC | $19.66 | 2025 | Vashe Wound Solution 250 Ml (8.5 Fl Oz) Flip Top Cap |
| Cumberland Pharmaceuticals, INC. | $17.14 | 2020 | |
| Ferring Pharmaceuticals INC. | $17.10 | 2023 | Rebyota |
| Tetraphase Pharmaceuticals, INC. | $17.07 | 2020 | |
| Pfizer INC. | $16.39 | 2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $15.00 | 2019 | |
| Daiichi Sankyo INC. | $13.82 | 2022 | |
| Emd Serono, INC. | $13.28 | 2019 | |
| Theratechnologies INC. | $13.13 | 2019 | |
| Genentech USA, INC. | $11.93 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Athanasios Papastamelos listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.